{
  "completed": true,
  "status": "documented_historical_discovery_and_reconciliation",
  "provider": "Consensus",
  "provider_mode": "Historical browser/connector use as recorded in the source artifacts",
  "local_audit_date": "2026-10-09",
  "primary_comparison_count": null,
  "reported_usage": [],
  "grade_changed": false,
  "score_before": {
    "hsef_level": "Γ",
    "hsef_descriptor": "Mechanistically plausible, partial system support",
    "confidence": "Moderate",
    "confidence_rationale": "60 primary reports with 4 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.",
    "rests_on_non_peer_reviewed_work": false,
    "rationale": "The registered weakest-link conjunction returns Γ. All four therapeutic/mechanism clauses remain Γ under rubric 07, though cell/rodent plasticity and some clinical package effects are empirically positive. Primary-SC2 and scope-matched sensitivities also return Γ. The unresolved content is required formal consolidation, not whether the drug ever changes synapses or symptoms."
  },
  "score_after": {
    "hsef_level": "Γ",
    "hsef_descriptor": "Mechanistically plausible, partial system support",
    "confidence": "Moderate",
    "confidence_rationale": "60 primary reports with 4 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.",
    "rests_on_non_peer_reviewed_work": false,
    "rationale": "The registered weakest-link conjunction returns Γ. All four therapeutic/mechanism clauses remain Γ under rubric 07, though cell/rodent plasticity and some clinical package effects are empirically positive. Primary-SC2 and scope-matched sensitivities also return Γ. The unresolved content is required formal consolidation, not whether the drug ever changes synapses or symptoms."
  },
  "independent_blinded_audit": false,
  "raw_receipts": [
    {
      "path": "deliverables\\hsef_v53_popularity_batch_2026-10-04\\psilocybin-dual-phase\\consensus-initial-raw.json",
      "sha256": "5086435399bda824a3de464637e0a4bcdd67b019bb5c47c0d3be745910bc6e32"
    },
    {
      "path": "deliverables\\hsef_v53_popularity_batch_2026-10-04\\psilocybin-dual-phase\\consensus-targeted-raw.json",
      "sha256": "07e09c89874d0ab22a718b8395b78e50aae299f85a53a6e76b0ba5cd48a5c9ed"
    },
    {
      "path": "deliverables\\hsef_v53_popularity_batch_2026-10-04\\psilocybin-dual-phase\\consensus\\evidence-cards.json",
      "sha256": "0eab8b9383bee5764d5a5cda5eee1cb9626c178a85fae8a895053389079c0c8a"
    },
    {
      "path": "deliverables\\hsef_v53_popularity_batch_2026-10-04\\psilocybin-dual-phase\\consensus\\evidence-cards.md",
      "sha256": "ee87b8929e3f11a6283798bcb1590ee22a345a09a3e48533b46ef8222419d560"
    },
    {
      "path": "deliverables\\hsef_v53_popularity_batch_2026-10-04\\psilocybin-dual-phase\\consensus\\rejections.json",
      "sha256": "58ef13cc34d9f7be17f9838d4b3b69fa8b2b14e931f6c0031c1f041a7c436c69"
    }
  ],
  "limitations": "This verifies documented historical use and links the record to the final edition. It adds no primary-source, full-text, independence or verification credit. Original access remains limited to the source-specific record."
}